Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 216

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 216
---

    with management and the independent registered public accounting firm the results of the annual audit, including our annual financial
    statements and related disclosures, and the results of the review by the independent registered public accounting firm of our quarterly
    financial statements and related disclosures;

    ●
    discussing with management
    and the independent registered public accounting firm the adequacy of our internal control over financial reporting, disclosure controls
    and procedures, compliance with legal and regulatory requirements, and code of business conduct and ethics;

    ●
    discussing with management
    and the independent registered public accounting firm our risk management policies;

    ●
    establishing policies regarding
    hiring employees from the independent registered public accounting firm and procedures for the receipt and retention of accounting
    related complaints and concerns;

    ●
    meeting independently with
    our independent registered public accounting firm and management;

    ●
    reviewing and providing
    oversight of any related person transactions, including establishing such policies and procedures as appropriate to facilitate such
    review; and

    ●
    preparing the audit committee
    report required by the SEC rules (which is included on page 11 of this proxy statement).

The
Audit Committee charter is available on the Investors page of our website at www.indaptusrx.com. The members of the Audit Committee
are Mr. Hayes, Ms. Karah, and Dr. Martell. Mr. Hayes serves as the Chairperson of the committee. Our Board has affirmatively determined
that each of Mr. Hayes, Ms. Karah, and Dr. Martell is independent for purposes of serving on an audit committee under Rule 10A-3 promulgated
under the Exchange Act and the Nasdaq Rules, including those related to Audit Committee membership.

The
members of our Audit Committee meet the requirements for financial literacy under the applicable Nasdaq rules. In addition, our Board
of Directors has determined that Mr. Hayes qualifies as an “audit committee financial expert,” as such term is defined in
Item 407(d)(5) of Regulation S-K, and under the similar Nasdaq Rules requirement that the Audit Committee have a financially sophisticated
member.

78

Compensation
Committee

Our
Compensation Committee is responsible for assisting the Board in the discharge of its oversight responsibilities relating to the evaluation
of our executive officers (including the Chief Executive Officer), determining the compensation of our executive officers, and overseeing
the management of risks associated therewith. In fulfilling